Cerier Emily, Lampert Brent C, Kilic Arman, McDavid Asia, Deo Salil V, Kilic Ahmet
Emily Cerier, Asia McDavid, Ahmet Kilic, Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
World J Cardiol. 2016 Dec 26;8(12):695-702. doi: 10.4330/wjc.v8.i12.695.
Advanced heart failure has been traditionally treated via either heart transplantation, continuous inotropes, consideration for hospice and more recently via left ventricular assist devices (LVAD). Heart transplantation has been limited by organ availability and the futility of other options has thrust LVAD therapy into the mainstream of therapy for end stage heart failure. Improvements in technology and survival combined with improvements in the quality of life have made LVADs a viable option for many patients suffering from heart failure. The question of when to implant these devices in those patients with advanced, yet still ambulatory heart failure remains a controversial topic. We discuss the current state of LVAD therapy and the risk vs benefit of these devices in the treatment of heart failure.
传统上,晚期心力衰竭的治疗方法包括心脏移植、持续使用正性肌力药物、考虑临终关怀,以及最近采用的左心室辅助装置(LVAD)。心脏移植受到器官可用性的限制,而其他选择的无效性已将LVAD治疗推向了终末期心力衰竭治疗的主流。技术进步和生存率的提高,以及生活质量的改善,使LVAD成为许多心力衰竭患者的可行选择。对于那些患有晚期但仍能走动的心力衰竭患者,何时植入这些装置的问题仍然是一个有争议的话题。我们讨论了LVAD治疗的现状以及这些装置在心力衰竭治疗中的风险与益处。